SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Stintzing Sebastian)
 

Sökning: WFRF:(Stintzing Sebastian) > Metastatic colorect...

Metastatic colorectal cancer : Advances in the folate-fluoropyrimidine chemotherapy backbone

Glimelius, Bengt (författare)
Uppsala universitet,Experimentell och klinisk onkologi
Stintzing, Sebastian (författare)
Charite Univ Med Berlin, Dept Hematol Oncol & Tumor Immunol CCM, Berlin, Germany.
Marshall, John (författare)
Georgetown Univ, Med Ctr, Washington, DC USA.
visa fler...
Yoshino, Takayuki (författare)
Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan.
de Gramont, Aimery (författare)
Hop Francobritannique, Lavallois Perret, France.
visa färre...
 (creator_code:org_t)
Elsevier, 2021
2021
Engelska.
Ingår i: Cancer Treatment Reviews. - : Elsevier. - 0305-7372 .- 1532-1967. ; 98
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • Notwithstanding recent treatment advances in metastatic colorectal cancer (mCRC), chemotherapy with a combination of a fluoropyrimidine and a folate agent, often 5-fluorouracil (5-FU) and leucovorin, remains the backbone of treatment regimens for the majority of patients with mCRC. This is despite a recent focus on molecular-targeted treatments and patient stratification according to mutational status or expression levels of specific genes. Intracellular folate concentration was discovered to be pivotal in the cytotoxic efficacy of 5-FU, paving the way to the current standard combination therapy approach. Subsequent discovery that systemic chemotherapy agents, such as irinotecan and oxaliplatin, can further increase the efficacy of 5-FU-based treatments led to the development of several combination chemotherapy regimens, including FOLFOX, FOLFIRI and FOLFOXIRI. Subsequent efforts to optimise 5-FU-based treatments have focused on 5-FU analogues, initially capecitabine and the combination drug tegafur/gimeracil/oteracil (S-1) and then TAS-102, which has recently been evaluated in phase 3 clinical trials for refractory colorectal cancer. Further approaches taken to improve the efficacy of 5-FU chemotherapy regimens have focused on optimising the route and dosing schedules and regulating folate metabolism. Pharmacokinetic variability caused by the requirement for metabolic conversion of leucovorin has been central to recent research, and the development of agents such as arfolitixorin which bypass the need for metabolic conversion remains promising for future therapeutic candidates. In this review, we summarise the evidence leading to the current treatment regimens employing 5-FU and leucovorin, focusing on recent approaches taken to optimise and refine treatments to improve clinical outcomes in patients with mCRC.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)

Nyckelord

Metastatic colorectal cancer
5-fluorouracil
Leucovorin
Chemotherapy

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy